Why gene therapy is no longer a pipe dream
By Michael White,
Pacific Standard Magazine
| 01. 18. 2018
Last year will be remembered for many things, many of them not good. But here's at least one flicker of hope: 2017 may go down as the year gene therapy finally turned a corner. In late December, the Food and Drug Administration announced its approvalof the third gene therapy since August. These three therapies—two for treating cancer and one for treating a form of congenital blindness—are the first of their kind to pass muster with the FDA. And with hundreds of clinical trials for other gene therapies underway, they won't be the last. For decades, gene therapy was a pipe dream, symbolizing the unfulfilled promises of biomedical scientists who claimed that they could not just treat but actually cure disease by fixing genes. Those promises are finally beginning to be realized.
The logic behind gene therapy is simple. Many diseases are caused by a missing or defective gene; replace the broken gene with a working copy, and you cure the disease. But putting this logic into practice hasn't been so easy. For more than a century...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...